Clinical Trial Update: A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment [Phase 1]

View source ↗

Summary

Phase 1 study of RG002C0106 injection in adults with normal renal function and mild-to-moderate renal impairment; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy
• Renal Impairment

Drugs mentioned

• RG002C0106 injection (RG002C0106)

Snippet

Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Conditions: Renal Impairments, IgA Nephropathy (IgAN) | Phase 1 | Status: NOT_YET_RECRUITING